Definium Therapeutics, Inc. Announces Closing of $805 Million Upsized Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

Definium Therapeutics has secured a massive $805 million from its upsized public offering, reflecting investor confidence in its innovative approach to psychiatric and neurological treatments. This significant capital influx will likely bolster its ongoing and future clinical trials, accelerating the development of its new generation of therapeutics. The move underscores the growing demand for advanced biopharmaceutical solutions and could position Definium as a key player in this critical sector.